Protagonist Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Farallon Capital Management, L.L.C. and associated entities have reported a beneficial ownership of 9.99% in Protagonist Therapeutics, Inc. as of June 30, 2026.
NASDAQ
State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 5.2% of Protagonist Therapeutics Inc. common stock as of June 30, 2026.
NASDAQ
State Street Corporation has reported beneficial ownership of 4.9% of Protagonist Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.09% of Protagonist Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
Vanguard Portfolio Management has reported beneficial ownership of 5.53% of Protagonist Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group reports 0% beneficial ownership in Protagonist Therapeutics Inc. following an internal realignment.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. filed an amended Schedule 13G, disclosing a continued 8.1% beneficial ownership in Protagonist Therapeutics, Inc.
NASDAQ
Wellington Management Group LLP and its affiliates have reported a 5.1% beneficial ownership stake in Protagonist Therapeutics, Inc. common stock.
NASDAQ
Farallon Capital Management entities updated their beneficial ownership of Protagonist Therapeutics, Inc. common stock, reflecting internal management changes.
NASDAQ
The Vanguard Group reported an 8.65% beneficial ownership stake in Protagonist Therapeutics Inc. as of December 31, 2025, following an internal realignment.
NASDAQ
Biotechnology Value Fund and its affiliates have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 4.1% in Protagonist Therapeutics, Inc. as of September 30, 2025.
NASDAQ
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, reported a 2.76% beneficial ownership stake in Protagonist Therapeutics, Inc. as of September 30, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts Protagonist Therapeutics Stake to 13.8%
BlackRock, Inc. has reported an increased beneficial ownership of 13.8% in Protagonist Therapeutics, Inc., holding 8,575,669 shares of common stock.
NASDAQ
State Street Corporation has reported a 5.2% beneficial ownership stake in Protagonist Therapeutics Inc. common stock.
NASDAQ
SCHEDULE 13G: Biotechnology Value Fund Group Discloses 5.2% Passive Stake in Protagonist Therapeutics
A group of investment entities led by Biotechnology Value Fund L.P. and Mark N. Lampert has disclosed a collective 5.2% passive ownership stake in Protagonist Therapeutics, Inc.
NASDAQ
State Street Corporation has filed a Schedule 13G, reporting a 4.4% passive beneficial ownership stake in Protagonist Therapeutics Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Amends Stake in Protagonist Therapeutics, Disclosing 14.8% Beneficial Ownership
BlackRock, Inc. has filed an amendment to its Schedule 13G, revealing a 14.8% beneficial ownership stake in Protagonist Therapeutics, Inc. as of March 31, 2025.
NASDAQ
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a collective beneficial ownership of 5.29% in Protagonist Therapeutics, Inc.'s common stock.
NASDAQ
SCHEDULE 13G/A: Farallon Capital Reports 9.99% Stake in Protagonist Therapeutics, Including Warrants
Farallon Capital and its affiliated entities have disclosed a significant beneficial ownership stake of 9.99% in Protagonist Therapeutics, Inc., comprising common shares and exercisable warrants as of December 31, 2024.
NASDAQ
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting a 16.6% beneficial ownership stake in Protagonist Therapeutics, Inc. as of December 31, 2024.